Most Recent
German drug company Merck KGaA has filed a massive trade mark lawsuit against US pharmaceutical giant Merck Sharpe & Dohme in Australian federal court, claiming its use of the trade marked term "Merck" throughout its websites and apps accessible in Australia violates its trade mark and a 1970 agreement between the two.
The Office of the Australian Information Commissioner has confirmed a news report that it received a notice of a health data breach every other day after its mandatory data breach scheme took effect.
A lawyer for the University of Sydney has attacked ObjectiVision for failing to produce any commercial benefits from the glaucoma detection method at the centre of a patent infringement dispute, despite holding exclusive rights to the technology for 11 years.
Expert witnesses were pitted against each other Wednesday at a trial alleging generic makers infringed a patent covering the anti-depressant Lexapro, and Apotex' consultant took the brunt of it.
The maker of the anti-depressant Lexapro faced off Monday against Apotex, Aspen Pharma and Sandoz at a court hearing over the rights to make generic versions of the top-selling product, with a barrister for Lundbeck slamming the three companies' defence that their drugs were different.
The applicants in a class action against Johnson & Johnson over allegedly defective vaginal mesh products have won court approval to expand the size of the class and seek an order blocking the sale of devices that don't include a proper warning.
A long-awaited congressional report has called for an overhaul of medical device regulation in Australia, in the wake of a system-wide failure to protect women who suffered "devastating" consequences after being implanted with faulty vaginal mesh products.
Biogen said Thursday it will pull its multiple sclerosis drug Zinbryta in Australia, nearly two weeks after the biotech company issued a worldwide withdrawal of the drug following reports of encephalitus in Europe.
As Shine Lawyers awaits judgment in a marathon class action against Johnson & Johnson over its pelvic mesh implants, a separate class action by the firm kicked into gear Wednesday when a judge gave the ok to serve court papers on US-based American Medical Systems.
GlaxoSmithKline and Novartis have made another admission in a case brought by the ACCC alleging the drug giants made misleading claims in marketing their Voltaren Osteo Gel and Voltaren Emulgel pain relief products.